The association of endoscopic and histologic endpoints with faecal calprotectin and C-reactive protein in patients with moderately to severely active ulcerative colitis treated with mirikizumab

被引：0
|
作者：
Panaccione, R. [1 ]
Sapin, C. [2 ]
Chan-Diehl, F. W. [3 ]
Moses, R. E. [3 ]
Siegmund, B. [4 ]
Walsh, A. [5 ]
Kobayashi, T. [6 ]
Parambir, D. S. [7 ]
Travis, S. [8 ]
机构：
[1] Univ Calgary, Cumming Sch Med, Fac Med, Calgary, AB, Canada
[2] Eli Lilly France, Rheumatol Gastroenterol Real World Access Analyt, Neuilly Sur Seine, France
[3] Eli Lilly & Co, Gastroenterol, Indianapolis, IN USA
[4] Univ Med Berlin, Medizin Klin Gastroenterol Infektiol, Rheumatol Charite, Berlin, Germany
[5] Nuffield Hlth Manor Hosp, Translat Gastroenterol Unit, Oxford, England
[6] Kitasato Univ, Gastroenterol, Kitasato Inst Hosp, Tokyo, Japan
[7] Northwestern Univ, Gastroenterol & Hepatol, Feinberg Sch Med, Chicago, IL USA
[8] Univ Oxford, Nuffield Dept Med, Oxford, England
来源：
JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
DOP90
引用
收藏
页码：I167 / I168
页数：2
相关论文
共 50 条
  • [31] C-reactive protein in children with active ulcerative colitis Reply
    Tsampalieros, Anne
    Griffiths, Anne
    Barrowman, Nick
    Mack, David R.
    JOURNAL OF PEDIATRICS, 2012, 160 (03): : 530 - 531
  • [32] Extended induction treatment with mirikizumab in patients with moderately to severely active ulcerative colitis: results from a Phase 2 trial
    Sandborn, W. J.
    Ferrante, M.
    Bhandari, B. R.
    Berliba, E.
    Hibi, T.
    D'Haens, G. Geert R.
    Tuttle, J.
    Krueger, K.
    Friedrich, S.
    Durante, M.
    Arora, V.
    Feagan, B.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S54 - S54
  • [33] REDUCTION IN INFLAMMATORY BIOMARKERS IN A PHASE 2 STUDY OF MIRIKIZUMAB IN THE TREATMENT OF PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS
    Sandborn, William J.
    Sands, Bruce E.
    Kobayashi, Taku
    Tuttle, Jay
    Schmitz, Jochen
    Durante, Michael
    Higgs, Richard E.
    Canavan, James
    Siegel, Robert
    Ferrante, Marc
    GASTROENTEROLOGY, 2019, 156 (06) : S1094 - S1095
  • [34] Early Symptom Control With Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis in the LUCENT-1 Induction Trial
    Danese, Silvio
    Dignass, Axel
    Matsuoka, Katsuyoshi
    Ferrante, Marc
    Long, Millie
    Redondo, Isabel
    Gibble, Theresa Hunter
    Moses, Richard
    Morris, Nathan
    Li, Xingyuan
    Milch, Catherine
    Abreu, Maria T.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S535 - S535
  • [35] EXTENDED TREATMENT WITH MIRIKIZUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 2 TRIAL
    Sandborn, William J.
    Ferrante, Marc
    Bhandari, Bal R.
    Berliba, Elina
    Hibi, Toshifumi
    D'Haens, Geert R.
    Tuttle, Jay
    Krueger, Kathryn A.
    Friedrich, Stuart
    Durante, Michael
    Arora, Vipin
    Feagan, Brian G.
    GASTROENTEROLOGY, 2019, 156 (06) : S1094 - S1094
  • [36] ACHIEVEMENT OF CORTICOSTEROID-FREE CLINICAL, ENDOSCOPIC, AND HISTOLOGIC OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH RISANKIZUMAB: RESULTS FROM THE COMMAND STUDY
    Loftus, Edward V.
    Parkes, Gareth C.
    Ferrante, Marc
    Panes, Julian
    Dubinsky, Marla C.
    Tanida, Satoshi
    Kalabic, Jasmina
    Zhang, Yafei
    Vladea, Ramona C.
    Hecht, Patrick
    Schreiber, Stefan
    GASTROENTEROLOGY, 2024, 166 (05) : S796 - S797
  • [37] BUDGET IMPACT OF MIRIKIZUMAB-MRKZ IN THE TREATMENT OF ADULT PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED STATES
    Stargardter, Matthew
    Upadhyay, Navneet
    Raj, Sayooj
    Fisher, Deborah
    Creveling, Thomas
    Bires, Nicholas
    Johnson, Nate
    Milev, Sandra
    GASTROENTEROLOGY, 2024, 166 (03) : S60 - S60
  • [38] Histological Outcomes and Predictive Value of Faecal Markers in Moderately to Severely Active Ulcerative Colitis Patients Receiving Infliximab
    Magro, Fernando
    Lopes, Susana Isabel
    Lopes, Joanne
    Portela, Francisco
    Cotter, Jose
    Lopes, Sandra
    Moreira, Maria Joao
    Lago, Paula
    Peixe, Paula
    Albuquerque, Andreia
    Rodrigues, Susana
    Silva, Mario Rui
    Monteiro, Pedro
    Lopes, Castro
    Monteiro, Lucilia
    Macedo, Guilherme
    Veloso, Luis
    Camila, Claudia
    Afonso, J.
    Geboes, Karel
    Carneiro, Fatima
    JOURNAL OF CROHNS & COLITIS, 2016, 10 (12): : 1407 - 1416
  • [39] Mirikizumab Improves Patient Assessments of Disease Severity and Change in Disease Activity in Patients With Moderately-to-Severely Active Ulcerative Colitis
    Travis, Simon
    Wu, Jianmin
    Sapin, Christophe
    Gibble, Theresa Hunter
    Hibi, Toshifumi
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 : S30 - S31
  • [40] C-REACTIVE PROTEIN LEVELS AND PARTIAL MAYO SCORE AS EARLY PREDICTORS OF CLINICAL AND ENDOSCOPIC OUTCOMES IN ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH TOFACITINIB: A POST HOC ANALYSIS OF OCTAVE INDUCTION 1&2
    Dubinsky, Marla C.
    Hudesman, David
    Steinwurz, Flavio
    Kulisek, Nicole
    Salese, Leonardo
    Paulissen, Jerome
    Su, Chinyu
    de Leon, Dario Ponce
    Magro, Fernando
    GASTROENTEROLOGY, 2020, 158 (06) : S1196 - S1197
12345